Bioptimus Unites AI Titans and Bio-Pharma Visionaries to Forge the Future of Biological AI

Paris, France – In a groundbreaking move set to redefine the landscape of biological research and drug discovery, Bioptimus, a pioneering force in artificial intelligence for biology, has officially announced the formation of its elite Scientific Advisory Board (SAB). This unparalleled assembly of global leaders in AI, machine learning, and biopharmaceutical R&D is tasked with steering Bioptimus in its ambitious mission: to build the next generation of AI foundation models that will unlock the deepest secrets of biological systems.

The convergence of cutting-edge AI and the vast, intricate world of biology holds the promise of unprecedented breakthroughs in human health.

Bioptimus stands at the forefront of this revolution, aiming to leverage the power of large language models (LLMs) – similar to those transforming natural language processing – to interpret, predict, and innovate within multimodal biological data. This includes everything from genomics and proteomics to clinical data and beyond, painting a holistic picture of life's complexities.

The sheer caliber of the individuals joining Bioptimus’s SAB underscores the company’s commitment to scientific rigor and audacious innovation.

At the helm of this advisory panel is Yoshua Bengio, a towering figure in the AI community and recipient of the Turing Award, widely considered the Nobel Prize of computing. As the Scientific Director of MILA (Quebec AI Institute), Bengio's insights into deep learning and AI ethics will be invaluable in shaping Bioptimus's foundational approach.

Joining him is an extraordinary roster of experts:

• Arthur Gretton, Professor of Machine Learning at UCL and a DeepMind Fellow, brings his profound understanding of kernel methods, causal inference, and advanced machine learning theory.
• Laurence Devillers, Professor at Sorbonne University and a renowned specialist in Human-Machine Interaction, will ensure a human-centric and ethically sound development of Bioptimus's AI models.
• Patrick Schwab, Chief AI Scientist at Siemens Healthineers, offers unparalleled expertise in applying AI to real-world healthcare challenges, from medical imaging to digital health solutions.
• Antoine Bordes, VP and Head of AI at Meta Paris, contributes extensive knowledge in large language models and the dynamics of cutting-edge AI research.
• Laurent Sanchez-Palencia, former Global Head of Research and Early Development at Sanofi, provides critical industry perspective, bridging the gap between scientific innovation and the practicalities of drug discovery and clinical development.

This formidable team will guide Bioptimus's scientific direction, ensuring the robustness and ethical integrity of its AI models.

Their collective wisdom will be crucial in navigating the complexities of biological data and accelerating the company’s goal of creating a unified, multi-modal AI model for biology. This model is designed to integrate diverse data sources seamlessly, offering a comprehensive understanding that current fragmented approaches cannot match.

Founded by a visionary team including Jean-Philippe Vert (Chief Impact Officer, Owkin), Thomas Clozel (CEO, Owkin), Rodolphe Katra, and Marc Atger, Bioptimus has already secured a substantial €35 million seed round.

This funding, led by Sofinnova Partners and Bpifrance, signals strong confidence in the company’s potential to revolutionize drug discovery, personalize medicine, and ultimately, significantly improve patient outcomes.

The establishment of this Scientific Advisory Board marks a pivotal moment for Bioptimus and for the broader field of AI in life sciences.

By bringing together such an elite group, Bioptimus is not just building AI models; it is constructing a bridge to a future where biological mysteries are rapidly deciphered, and life-changing therapies are developed with unprecedented speed and precision. The journey ahead promises to be transformative, with this powerhouse team at the helm.